{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:23:37Z","timestamp":1760142217602,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.soncn.2021.151131","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T23:04:37Z","timestamp":1616886277000},"page":"151131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immune Checkpoint Inhibitor-Related Adrenal Insufficiency"],"prefix":"10.1016","volume":"37","author":[{"given":"Grace","family":"Cherry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.soncn.2021.151131_bib0001","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soncn.2021.151131_bib0002","unstructured":"Opdivo Full Prescribing Information. Available at: https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf. (Accessed January 10, 2021) 2021."},{"key":"10.1016\/j.soncn.2021.151131_bib0003","unstructured":"Pembrolizumab Full Prescribing Information. Available at: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf. (Accessed January 23, 2021) 2021."},{"key":"10.1016\/j.soncn.2021.151131_bib0004","unstructured":"Ipilimumab Full Prescribing Information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125377s110lbl.pdf. (Accessed January 23, 2021) 2021."},{"year":"2021","series-title":"FDA Approval Timelines of Active Immunotherapies","key":"10.1016\/j.soncn.2021.151131_bib0005"},{"year":"2021","series-title":"NCCN Guidelines Version 1.2021. Management of Immunotherapy-Related Toxicities","key":"10.1016\/j.soncn.2021.151131_bib0006"},{"year":"2021","series-title":"Physiology, endocrine hormones","author":"Campbell","key":"10.1016\/j.soncn.2021.151131_bib0007"},{"key":"10.1016\/j.soncn.2021.151131_bib0008","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.soncn.2021.151131_bib0009","first-page":"16","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"2016","author":"Trainer","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.soncn.2021.151131_bib0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.amjmed.2015.08.021","article-title":"Adrenal crisis: still the deadly event in the 21st century","volume":"129","author":"Puar","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.soncn.2021.151131_bib0011","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S2213-8587(14)70142-1","article-title":"Diagnosis and management of adrenal insufficiency","volume":"3","author":"Bancos","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.soncn.2021.151131_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-228135","article-title":"Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer","volume":"12","author":"Chang","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.soncn.2021.151131_bib0013","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1159\/000507652","article-title":"Primary adrenal insufficiency during immune checkpoint inhibitor treatment: case reports and review of the literature","volume":"13","author":"Salinas","year":"2020","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.soncn.2021.151131_bib0014","doi-asserted-by":"crossref","DOI":"10.1080\/14712598.2021.1869211","article-title":"Hypophysitis related to immune checkpoint inhibitors: an intriguing adverse event with many faces [published online ahead of print]","author":"Deligiorgi","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.soncn.2021.151131_bib0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.soncn.2021.151131_bib0016","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.3390\/ijms21124427","article-title":"Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials","volume":"21","author":"Kooshkaki","year":"2020","journal-title":"J Mol Sci"},{"key":"10.1016\/j.soncn.2021.151131_bib0017","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.soncn.2021.151131_bib0018","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.soncn.2021.151131_bib0019","doi-asserted-by":"crossref","DOI":"10.1080\/14712598.2021.1869211","article-title":"Hypophysitis related to immune checkpoint inhibitors: an intriguing adverse event with many faces [published online ahead of print]","author":"Deligiorgi","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.soncn.2021.151131_bib0020","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.soncn.2021.151131_bib0021","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Dalmazi","year":"2019","journal-title":"Expert Rev Endocrinol Metab"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208121000140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208121000140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:37:20Z","timestamp":1760081840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208121000140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0749208121000140"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2021.151131","relation":{},"ISSN":["0749-2081"],"issn-type":[{"type":"print","value":"0749-2081"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitor-Related Adrenal Insufficiency","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2021.151131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151131"}}